Infectious Disease Alert – October 1, 2006
October 1, 2006
View Archives Issues
-
Darunavir (TMC114) Approved by the FDA
Darunavir (known during development as TMC114 and given the proprietary name, PREZISTA-TM) was approved by FDA on June 23, 2006, for use in combination with other antiretroviral agents for the treatment of HIV infection in adults. -
CDAD: Novel Therapeutics
Lagrotteria and colleagues enrolled 39 inpatients with a primary episode of Clostridium difficile-associated diarrhea (CDAD) to receive treatment for 10 days with either metronidazole (MET) alone or together with rifampin (RIF). -
Preventing Fungal Infection: Does Clean Air Matter?
It is widely accepted that vulnerable patients are best protected from acquiring invasive mold diseases by placing them in a protected environment, supplying sterile air by means of HEPA filtration with or without laminar air flow (LAF). However, there is little to support this contention. -
Hepatocyte Apoptosis in Hepatitis C/HIV Co-Infection
This interesting paper from Groopman's laboratory at Beth Israel in Boston, reports the results of some elegant experiments designed to elucidate potential mechanisms, accounting for the innocent bystander hepatocyte apoptosis previously observed as a result of binding of HCV and HIV proteins. -
Update on the CNS Adverse Effects of Sustiva® (Efavirenz)
The US Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents recommends efavirenz (EFV) as part of the preferred non-nucleoside reverse transcriptase inhibitor-based regimen for HIV patients. -
Updates By Carol A. Kemper, MD, FACP
The only manufacturer of VZIG in the United States recently stopped its production. An alternate product, VariZIG, which is manufactured by a Canadian company and has not been approved for use in the United States by the FDA, can be obtained in the United States, but only through expanded access as an investigational new drug. -
Pharmacology Watch: The Indictment of Pharma Industry Marketing Practices
TNF Blockers: Should You Be Concerned?; FDA Actions -
Clinical Briefs in Primary Care supplement
What is the Best Way to 'Predict' Diabetes: IFG, IGT, or A1c?; Hair Growth With Finasteride: Not Just More, but More Better!; Prevalence of Diabetic Neuropathy; Hypogonadism is Surprisingly Common in Middle-Aged Men; Carpal Tunnel Syndrome: Capturing the Benefits of MultiModal Treatment; Diastolic Dysfunction: Not So Benign